Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYVIBE-010 adjuvant MK-7684A versus pembrolizumab in high-risk melanoma
CTR20231034Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of vibostolimab, pembrolizumab in cutaneous melanoma (CM), sponsored by Merck & Co.. Started Jun 2023; status: completed.
02
Drugs
vibostolimabpembrolizumab
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on CTR20231034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231034.